Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Clozapine is an effective antipsychotic for Parkinson's disease (PD) that does not worsen motor function and can improve tremor. It is approved for PD psychosis in Europe and Australia.
Objective: The aim of this study was to report on the use of clozapine in a movement disorder clinic.
Methods: We report on patients monitored during the COVID-19 pandemic in clinic over a 7-month period.
Results: Sixty-five patients were seen, of whom 50 had PD. Thirty-one were treated for psychosis, 18 for refractory tremor and 1 for levodopa dyskinesias. The remainder had psychotic symptoms with dementia with Lewy bodies (n = 2) or other movement disorders. Four had clozapine discontinued because of sedation and 1 for agranulocytosis. Three had clozapine temporarily halted because of granulocytopenia but were rechallenged successfully.
Conclusions: When comparing clozapine use in this clinic as compared with others, we deduce that clozapine is likely significantly underutilized in the United States.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/WNF.0000000000000510 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Twelve Anti-Dyskinetic Drugs in Parkinson's Disease: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Eur J Neurol
August 2025
Department of Neurology, Bishan Hospital of Chongqing Medical University, Chongqing, China.
Background: No comparative evaluations of anti-dyskinetic drugs to mitigate levodopa-induced dyskinesia (LID) and OFF time have been performed; head-to-head anti-dyskinetic trials are unlikely to be funded. We sought to compare the efficacy, tolerability, and safety of 12 anti-dyskinetic drugs for peak-dose dyskinesia and OFF time through a Bayesian network meta-analysis.
Methods: A network meta-analysis (NMA) was conducted for randomized controlled trials (RCTs) searched through the databases of MEDLINE, Embase, Cochrane Controlled Register of Controlled Trials from incipiency to January 2025.
A case of clozapine-induced stuttering in a HIV-positive individual.
S Afr J Psychiatr
July 2025
Department of Psychiatry, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Introduction: Stuttering, a speech disorder marked by disruptions in fluency, can be developmental or acquired. Acquired stuttering often stems from neurological causes, psychological trauma or certain medications, with antipsychotics such as clozapine implicated in several cases. Clozapine, particularly at higher doses, has been associated with dose-dependent stuttering although the precise mechanisms remain uncertain.
View Article and Find Full Text PDFRegulating astrocytic activity in the dorsal striatum mitigates L-dopa-induced dyskinesia in Parkinson's disease.
Sci Rep
July 2025
Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea.
In Parkinson's disease (PD), long-term 3,4-dihydroxy-L-phenylalanine (L-dopa) therapy leads to the development of motor complications, including L-dopa-induced dyskinesia (LID). Increased numbers of reactive astrocytes in the brains of patients with PD are a key feature of this disease. Astrocytes are involved in the development of LID; however, whether the regulation of astrocytic activity influences LID development remains unclear.
View Article and Find Full Text PDFDiscontinuation of the Clozapine Risk Evaluation and Mitigation Strategy and Implications in Movement Disorders.
Mov Disord Clin Pract
June 2025
Movement Disorders Division, Medical University of South Carolina Department of Neurology, Charleston, SC, USA.
Inhibition of the nucleus accumbens core with DREADDs after acute and repeated exposure to oxycodone reduces locomotor activity in female but not male Rattus norvegicus.
Neurosci Lett
August 2025
Department of Comparative Pathobiology, Cummings School of Veterinary Medicine, Tufts University, Grafton, MA, USA. Electronic address:
Opioid use disorder affects both men and women, but significant sex differences exist in addiction vulnerability and progression. The nucleus accumbens (NAc) plays a critical role in drug reward and motor outputs, yet its sex-specific functions in opioid response remain poorly understood. We investigated the role of the NAc in acute and repeated oxycodone response using chemogenetics in male and female Sprague Dawley rats.
View Article and Find Full Text PDF